Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Aglafoline inhibits in a concentration-dependent manner the aggregation and ATP release reaction induced in washed rabbit platelets by PAF (platelet-activating factor). The IC50 values of Aglafoline on PAF (3.6 nM)-induced platelet aggregation were about 50 μM.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 11,700 | 6-8周 | ||
50 mg | ¥ 15,300 | 6-8周 | ||
100 mg | ¥ 19,500 | 6-8周 |
产品描述 | Aglafoline inhibits in a concentration-dependent manner the aggregation and ATP release reaction induced in washed rabbit platelets by PAF (platelet-activating factor). The IC50 values of Aglafoline on PAF (3.6 nM)-induced platelet aggregation were about 50 μM. |
体外活性 | Aglafoline also inhibits [3H]PAF (3.6 nM) binding to washed rabbit platelets (IC50: 17.8 μM). The concentration-response curve of PAF-induced platelet aggregation was shifted to the right by Aglafoline (pA2: 5.97; pA10: 5.04). Although thromboxane B2 formation caused by collagen and thrombin was partially suppressed by Aglafoline, thromboxane B2 formation caused by ionophore A23187 and arachidonic acid was not affected. Aglafoline inhibited the [3H]inositol monophosphate formation caused by PAF but not that caused by collagen or thrombin in the presence of indomethacin (20 μM). |
体内活性 | The cAMP content of washed rabbit platelets was not affected by Aglafoline. Rat femoral intravenous administration of Aglafoline (10 mg/kg) did not affect blood pressure. However, Aglafoline (10 mg/kg) both prophylactically and therapeutically antagonized PAF (2.5 μg/kg)-induced hypotensive shock in rats. Intravenous PAF (30 ng/kg) caused severe bronchoconstriction in guinea pigs. This effect was completely blocked by Aglafoline. |
别名 | Rocaglamide U, Aglafolin, (-)-Methyl rocaglate |
分子量 | 492.52 |
分子式 | C28H28O8 |
CAS No. | 143901-35-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 100 mg/mL (203.04 mM), Sonication is recommended.
DMSO: 21.43 mg/mL (43.51 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.0304 mL | 10.1519 mL | 20.3037 mL | 50.7594 mL |
5 mM | 0.4061 mL | 2.0304 mL | 4.0607 mL | 10.1519 mL | |
10 mM | 0.203 mL | 1.0152 mL | 2.0304 mL | 5.0759 mL | |
20 mM | 0.1015 mL | 0.5076 mL | 1.0152 mL | 2.538 mL | |
Ethanol | 50 mM | 0.0406 mL | 0.203 mL | 0.4061 mL | 1.0152 mL |
100 mM | 0.0203 mL | 0.1015 mL | 0.203 mL | 0.5076 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Aglafoline 143901-35-3 Others Methyl rocaglate Rocaglamide U Aglafolin (-)-Methyl rocaglate Inhibitor inhibitor inhibit